Evidence map›Paper›PMID 42575990›Full record

ArticleCell death and differentiation2026

RNF5 promotes acute lung injury through HSPA5 ER-to-cytosol translocation and resultant PERK activation.

Ya-Zhou Sun, Xin-Yan Li, Jia Wang, Meng-Liu Zeng, Wei-Yi Qu, Xu Cheng, Lei Luo, Wei Wang, Juan Yang, Jun Zhang and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ya-Zhou Sun *State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Xin-Yan Li *State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Jia Wang *State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Meng-Liu Zeng *Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wei-Yi QuDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xu ChengState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Lei LuoDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Wei WangDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Juan YangState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Jun ZhangState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Han TianState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Peng ZhangTaikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China.ORCID http://orcid.org/0009-0006-9166-1489
Zhi-Gang SheState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China. zgshe@whu.edu.cn.ORCID http://orcid.org/0000-0001-9402-4166
Hongliang LiState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China. lihongliang@gmu.edu.cn.
Xiao-Jing ZhangState Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China. zhangxj@gimi.ac.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81770053National Natural Science Foundation of China (National Science Foundation of China) 81970364National Natural Science Foundation of China (National Science Foundation of China) 82100086National Natural Science Foundation of China (National Science Foundation of China) 82170595National Natural Science Foundation of China (National Science Foundation of China) 82260020National Natural Science Foundation of China (National Science Foundation of China) 82270390National Natural Science Foundation of China (National Science Foundation of China) 82370585National Natural Science Foundation of China (National Science Foundation of China) 82422013
6 · The paper itself

Abstract

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe conditions lacking specific pharmacological treatments. Endoplasmic reticulum (ER) stress plays a pivotal role in their pathophysiology, yet the precise regulatory mechanisms remain elusive. In this study, we identify the E3 ubiquitin ligase ring finger protein 5 (RNF5) as a critical driver of ALI/ARDS. RNF5 is markedly upregulated in response to ALI and significantly exacerbates lung injury by stabilizing HSPA5 (heat shock protein family A member 5), a master regulator of the unfolded protein response (UPR). Notably, in vivo Rnf5 ablation effectively attenuated pulmonary edema, inflammatory cell infiltration, and apoptosis, whereas lung-specific Rnf5 overexpression worsened inflammation and cell death in mice. Mechanistically, RNF5 interacts with HSPA5 and competitively blocks its binding to PERK, facilitating PERK release. Furthermore, RNF5 promotes the retro-translocation of HSPA5 from the ER lumen to the cytosol. In the cytosol, RNF5 mediates the K6- and K63-linked polyubiquitination of HSPA5, enhancing its thermal stability and preventing its re-entry into the ER. This spatial sequestration sustains the persistent dissociation of the PERK-HSPA5 complex, leading to the hyperactivation of the pro-apoptotic and pro-inflammatory PERK-eIF2α-CHOP signaling cascade. The ability of RNF5 to promote ALI is strictly dependent on its E3 ligase activity. In conclusion, our findings uncover a compartment-specific regulatory mechanism of HSPA5, suggesting that the RNF5-HSPA5-PERK axis represents a promising therapeutic target for ALI/ARDS.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.